Shares in Collagen Solutions PLC rose 13% after it unveiled a partnering deal in South Korea. Insung Medical will help commercialise the UK firm’s flagship product, ChondroMimetic. This is a minimally-invasive, surgically-placed scaffold for the repair of cartilage defects in the knee. To read the full article, click here.
CMAC (Continuous Manufacturing and Advanced Crystallisation), a pre-competitive consortium led by the University of Strathclyde to accelerate progress in pharmaceutical manufacturing, announces that Pfizer Inc has joined as a strategic member, alongside GSK, AZ, Novartis, Bayer, Takeda, Lilly and Roche. CMAC is a world-class national centre in advanced pharmaceutical manufacturing, focusing on accelerating the adoption of continuous manufacturing for the production of medicines with a...
A research breakthrough by scientists at the University of Dundee, St Andrews and Stony Brook may help to stop a potential modern epidemic in it’s tracks. The liver disease NASH is developed in approximately 10-15% of obese individuals with type-2 diabetes. “This condition is particularly sinister because it is difficult to identify affected patients, and even when a correct diagnosis is made there are currently...
The focus of the collaboration was to work together in the areas of immunology and inflammation medicine. The collaboration falls under the GLAZgo Discovery Unit, and the main goal is to identify new pathways by which inflammation can promote diseases. This will result in the creation of better medicines for patients. So how has this collaboration worked from then until now? Professor Carl S. Goodyear...
£3.8million boost in funding will advance development of next generation medical devices that monitor disease deep inside the lungs. The funding has been awarded by the Engineering and Physical Sciences Research Council (EPSRC) to continue to support the research for the next five years. The investment will enable researchers to further develop systems that could revolutionise how lung diseases are investigated, diagnosed and treated. It...
Scottish biotech TC BioPharm enters into a collaboration and license agreement with bluebird bio (NASDAQ:BLUE) aimed at advancing the former’s CAR-engineered gamma delta T cell program into the clinic and expanding blood cancer and solid tumor targets. The collaboration teams up Bluebird bio, who are one of several companies working on safer versions of CAR-T cells and TC BioPharm who are developing CAR-T technology called ImmuniCAR which uses gene therapy to...